Trials / Completed
CompletedNCT02595528
A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia
A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 163 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 40 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will identify the optimum concentrations of AGN-199201 and AGN-190584 when dosed in combination once a day for the improvement of uncorrected near visual acuity in participants with presbyopia (inability to focus on items close-up).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 ophthalmic solution | 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye. |
| DRUG | AGN-190584 ophthalmic solution | 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye. |
| DRUG | AGN-190584 vehicle | Vehicle to AGN-190584 |
| DRUG | AGN-199201 + AGN-190584 Combination | 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye. |
| DRUG | AGN-199201 vehicle | Vehicle to AGN-199201 |
Timeline
- Start date
- 2016-04-29
- Primary completion
- 2017-10-18
- Completion
- 2017-10-18
- First posted
- 2015-11-03
- Last updated
- 2020-12-22
- Results posted
- 2020-12-22
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02595528. Inclusion in this directory is not an endorsement.